JP2022509609A5 - - Google Patents
Info
- Publication number
- JP2022509609A5 JP2022509609A5 JP2021526584A JP2021526584A JP2022509609A5 JP 2022509609 A5 JP2022509609 A5 JP 2022509609A5 JP 2021526584 A JP2021526584 A JP 2021526584A JP 2021526584 A JP2021526584 A JP 2021526584A JP 2022509609 A5 JP2022509609 A5 JP 2022509609A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inhibitor
- shp2
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306558.0 | 2018-11-23 | ||
| EP18306558 | 2018-11-23 | ||
| PCT/EP2019/082180 WO2020104635A1 (en) | 2018-11-23 | 2019-11-22 | Use of shp2 inhibitors for the treatment of insulin resistance |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022509609A JP2022509609A (ja) | 2022-01-21 |
| JP2022509609A5 true JP2022509609A5 (https=) | 2022-09-28 |
| JP7454573B2 JP7454573B2 (ja) | 2024-03-22 |
Family
ID=64664217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526584A Active JP7454573B2 (ja) | 2018-11-23 | 2019-11-22 | インスリン抵抗性を処置するためのｓｈｐ２阻害剤の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20220000869A1 (https=) |
| EP (1) | EP3883574A1 (https=) |
| JP (1) | JP7454573B2 (https=) |
| WO (1) | WO2020104635A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| EP4496566A1 (en) * | 2022-03-21 | 2025-01-29 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of shp2 inhibitors for inhibiting senescence |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN117625770A (zh) * | 2022-08-26 | 2024-03-01 | 上海交通大学 | Ptpn11基因作为靶点在制备治疗药源性代谢综合征药物中的应用 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002506055A (ja) * | 1998-03-12 | 2002-02-26 | ノボ ノルディスク アクティーゼルスカブ | タンパク質チロシンホスファターゼ（ｐｔｐアーゼ）の調節剤 |
| US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
| US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
| US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
| US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
| US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
| CN100410236C (zh) * | 2002-01-29 | 2008-08-13 | 雪兰诺实验室有限公司 | 作为蛋白酪氨酸磷酸酶调节剂的取代亚甲基酰胺衍生物 |
| US7399586B2 (en) * | 2002-05-23 | 2008-07-15 | Ceptyr, Inc. | Modulation of biological signal transduction by RNA interference |
| US20080058431A1 (en) * | 2004-03-26 | 2008-03-06 | Gen-Sheng Feng | Modulators of Shp2 Tyrosine Phosphatase and Their Use in the Treatment of Body Weight Disorders |
| WO2007117699A2 (en) | 2006-04-07 | 2007-10-18 | University Of South Florida | Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-87877, nsc-117199 and their analogs |
| WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
| WO2015003094A2 (en) | 2013-07-03 | 2015-01-08 | Indiana University Research & Technology Corporation | Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors |
| US9932288B2 (en) | 2015-12-09 | 2018-04-03 | West Virginia University | Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent |
| NL2019390B1 (en) * | 2017-08-04 | 2019-02-21 | Univ Leiden | Screening Method |
| WO2019152454A1 (en) * | 2018-01-30 | 2019-08-08 | Research Development Foundation | Shp2 inhibitors and methods of use thereof |
-
2019
- 2019-11-22 JP JP2021526584A patent/JP7454573B2/ja active Active
- 2019-11-22 US US17/295,600 patent/US20220000869A1/en not_active Abandoned
- 2019-11-22 EP EP19805329.0A patent/EP3883574A1/en active Pending
- 2019-11-22 WO PCT/EP2019/082180 patent/WO2020104635A1/en not_active Ceased
-
2024
- 2024-08-20 US US18/809,948 patent/US20250090529A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022509609A5 (https=) | ||
| JP2023528039A5 (https=) | ||
| Yang et al. | Inhibition of non-ATG translational events in cells via covalent small molecules targeting RNA | |
| JP2021531022A5 (https=) | ||
| JP2012092348A5 (https=) | ||
| JP2008546390A5 (https=) | ||
| WO2006074330A3 (en) | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | |
| JP2013537423A5 (https=) | ||
| JP2012136542A5 (https=) | ||
| WO2006074244A3 (en) | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | |
| Azam et al. | Translation inhibition from a distance: the small RNA SgrS silences a ribosomal protein S1‐dependent enhancer | |
| WO2008109105A3 (en) | Methods and compositions for improved therapeutic effects with sirna | |
| MA32539B1 (fr) | Traitement du diabète chez des patients pour lesquels une thérapie par la metformine n'est pas appropriée | |
| JP2012512907A5 (https=) | ||
| JP2024023290A5 (https=) | ||
| JP2012505657A5 (https=) | ||
| JP2010500291A5 (https=) | ||
| CN114072404A (zh) | Ret选择性抑制剂及其制备方法和用途 | |
| JP2015504299A5 (https=) | ||
| Hermann | Viral RNA targets and their small molecule ligands | |
| DE502007001402D1 (de) | Aminoacyl-prodrug derivate und arzneimittel zur behandlung von thromboembolischen erkrankungen | |
| Qian et al. | The long non‐coding RNA HLNC1 potentiates hepatocellular carcinoma progression via interaction with USP49 | |
| Muench et al. | Quadruplex-forming oligonucleotide targeted to the VEGF promoter inhibits growth of non-small cell lung cancer cells | |
| JP2015504432A5 (https=) | ||
| Wu et al. | circ_CHFR regulates ox-LDL-mediated cell proliferation, apoptosis, and EndoMT by miR-15a-5p/EGFR axis in human brain microvessel endothelial cells |